BHPW
ABVX

Beverly Hills Private Wealth’s Abivax ABVX Stock Holding History

Beverly Hills Private Wealth’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,743
Closed -$235K – 348
2025
Q4 		$235K Buy
+1,743
New +$190K 0.04% 295

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Beverly Hills Private Wealth's ABVX Position: Q1 2026 in Review

Beverly Hills Private Wealth sold out of Abivax (ABVX) in Q1 2026, closing a stake of 1,743 shares — an estimated $235K sold.

Beverly Hills Private Wealth first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $235K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Beverly Hills Private Wealth reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Beverly Hills Private Wealth sold 1,743 Abivax shares in Q1 2026, an estimated $235K.
  • Beverly Hills Private Wealth first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
  • Beverly Hills Private Wealth's Abivax position peaked at $235K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Beverly Hills Private Wealth's 13F filing for Q1 2026, filed 4 May 2026.